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Abstract
Purpose: Despite its widespread use, the positron emission tomography (PET) radiotracer 2-deoxy-2-
[18F]fluoro-D-glucose ([18F]FDG) has been shown in clinical settings to be ineffective for improving early
diagnosis of pancreatic ductal adenocarcinoma (PDAC). A promisingbiomarker for PDACdetection is the
tight junction protein claudin-4. The purpose of this study was to evaluate a new single-photon emission
computed tomography (SPECT) imaging agent, [111In]anti-claudin-4mAb,with regard to its ability to allow
visualisation of claudin-4 in a xenograft and a genetically engineered mouse model of PDAC.
Procedures: The ability of [111In]anti-claudin-4 mAb to selectively target claudin-4 was assessed
using two human xenograft tumour models with differential claudin-4 status in mice. [111In]anti-
claudin-4 mAb was also used to detect PDAC development in genetically engineered KPC mice.
The PDAC status of these mice was confirmed with [18F]FDG-PET, magnetic resonance
imaging (MRI), histology, and immunofluorescence microscopy.
Results: High uptake of [111In]anti-claudin-4 mAb was observed in PDAC xenografts in mice,
reaching 16.9 ± 4.5 % of injected dose per gram (% ID/g) at 72 h post-injection. This uptake was
mediated specifically by the expression of claudin-4. Uptake of [111In]anti-claudin-4 mAb also
enabled clear visualisation of spontaneous PDAC formation in KPC mice.
Conclusions: [111In]anti-claudin-4 mAb allows non-invasive detection of claudin-4 upregulation
during development of PDAC and could potentially be used to aid in the early detection and
characterisation of this malignancy.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most lethal cancer types as it has an extremely poor 5-year
survival rate of G 5 % [1]. This dismal prognosis is due in
part to the asymptomatic progression of this malignancy in
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its early stages and the lack of adequate screening measures,
resulting in 80–90 % of patients being diagnosed when the
disease is already in an advanced, metastatic state. The
ability to identify PDAC early in its development has been
shown to improve outcome, particularly if the patient can be
diagnosed while still eligible for potentially curative surgical
resection [2]. At present, the most commonly utilised
imaging modality for suspected PDAC is x-ray computed
tomography (CT); however, it is now increasingly being
used in conjunction with positron emission tomography
(PET) to aid in early diagnosis and staging of this
malignancy [3, 4]. The PET radiotracer 2-deoxy-2-
[18F]fluoro-D-glucose ([18F]FDG) is the standard clinical
option for suspected PDAC; however, it has been shown to
be largely ineffective for the detection of small (≤ 20 mm)
pancreatic tumours, and in most cases inferior to conven-
tional CT and magnetic resonance imaging (MRI) for the
detection of liver, peritoneal and lung metastases. [18F]FDG
is also unable to distinguish focal mass-forming pancreatitis
from pancreatic cancer in most cases [5]. These limitations
strongly indicate the need for alternative biomarkers which
arise during the early stages of PDAC formation that can be
measured noninvasively by molecular imaging techniques.
Several gene expression analyses have shown that the
transmembrane protein claudin-4 is upregulated increasingly
throughout PDAC formation, including in the pre-invasive
pancreatic intraepithelial neoplastic (PanIn) lesions which
form before PDAC is established [6–10]. While this protein
is also present in healthy bladder, breast, prostate and
gastrointestinal mucosa, its expression levels in these
environments are very low in comparison to those in
pancreatic cancer tissues [11]. Claudin-4 therefore represents
an attractive biomarker for the early detection of PDAC. The
ability to detect claudin-4 upregulation may provide valuable
diagnostic and staging information which would supplement
conventional imaging procedures and impact on the clinical
decision-making process.
In pursuit of a claudin-4 imaging agent, we and others
have previously exploited the favourable binding character-
istics of the bacterial ligand Clostridium perfringens entero-
toxin (CPE). In 2013, Neesse et al. modified a C-terminal
fragment of CPE (cCPE) with the fluorophore Cy5.5 (Cy5.5-
GST-cCPE) and showed elevated uptake of this imaging
agent in PanIn lesions and PDAC compared to normal
pancreases in genetically engineered mouse models of
pancreatic cancer [12]. As clinical applications of fluores-
cence imaging are limited due to considerable signal
attenuation by tissue, we subsequently developed a cCPE
derivative modified with the single-photon emission com-
puted tomography (SPECT) radioisotope indium-111
([111In]cCPE-GST) [13]. Despite exhibiting a low binding
affinity (1.93 ± 0.59 μM), this radiotracer revealed claudin-
4-mediated tumour uptake in a variety of human cancer
xenograft and genetically engineered models which were all
found to have upregulated claudin-4 expression. However,
overall tumour uptake was generally low, and we have since
sought to investigate alternative claudin-4 targeting vectors
with improved target affinity and specificity.
Radiolabelled antibodies, given their superior affinity and
selectivity, have been used extensively as vectors for PET
and SPECT imaging [14]. Here, we report the preclinical
evaluation of an 111In-labelled anti-claudin-4 monoclonal
antibody with the aim of providing a new clinical tool for
improving upon early detection of PDAC. As in vivo
simulations of PDAC, we have used human pancreatic duct
epithelioid carcinoma xenografts in mice, and also a well-
validated, clinically relevant genetically engineered model of
PDAC (KPC model) [15] that develops a spectrum of
premalignant PanIN lesions which ultimately progress to
PDAC.
Materials and Methods
Materials
All reagents were purchased from Sigma-Aldrich unless
otherwise stated and were used without further purification.
The chelating agent p-SCN-Bn-DTPA was purchased from
Macrocyclics Inc. (Dallas, TX). Water was deionised using a
Barnstead NANOpure purification system (Thermo Scien-
tific) and had a resistance of 9 18.2 MΩ cm−1 at 25 °C.
Protein concentration measurements were made on a ND-
1000 spectrophotometer (NanoDrop Technologies, Inc.).
Instant thin-layer chromatography (iTLC) was performed
on glass microfiber chromatography paper (Agilent Tech-
nologies), and strips were analysed with either a Bioscan
AR-2000 radio-TLC scanner (Eckert & Ziegler) or a
Cyclone Plus Phosphor Imager (PerkinElmer). Radioactivity
measurements were determined using a CRC®-25R dose
calibrator (Capintec, Inc.).
Antibodies
The human MAB4219 antibody (R&D Systems) was used
as a targeting moiety for in vivo imaging of claudin-4 due to
its ability to recognise an epitope in the first extracellular
loop of the protein (aa Met29-Arg81). The reactivity of this
antibody for both murine and human claudin-4 was
confirmed by flow cytometry in claudin-4-expressing human
Panc-1 and murine 4T-1 cells (see Suppl. S1).
The status of claudin-4 expression in cells and tissue was
assessed by Western immunoblot and immunofluorescence
(see supplementary information for full experimental
protocols) using anti-claudin-4 antibodies 329400 and
PA5–28830 (ThermoFisher Scientific), respectively, since
MAB4219 does not perform in these techniques.
Radiolabelling
Modification of anti-claudin-4 mAb with p-SCN-Bn-DTPA
and subsequent radiolabelling with indium-111 were
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conducted following methods described by Brom et al. [16].
In brief, to a solution of anti-claudin-4 MAB4219 (200 μg)
or mouse IgG2A (200 μg, MAB003, R&D Systems) in 0.1 M
NaHCO3 (pH 9, 100 μl, Chelex treated) was added 20 M
equivalents of p-SCN-Bn-DTPA (245.6 μM) in anhydrous
dimethyl sulphoxide. The reaction mixture was incubated at
room temperature for 30 min with gentle shaking (450 rpm),
and the excess p-SCN-Bn-DTPA was removed by
Sephadex-G50 size exclusion chromatography (Sigma-Al-
drich). The affinity of the DTPA-conjugated MAB4219 for
claudin-4 was evaluated by flow cytometry in Panc-1 and
HT1080 cells and compared to that of the unmodified
antibody.
Indium-111 in 0.02 M hydrochloric acid (sourced from
Mallinckrodt Pharmaceuticals) was added to a 2-mg/ml
solution of the DTPA-modified antibody to achieve a ratio
of at least 1 MBq to 1 μg. The reaction mixtures were
incubated at room temperature for 1 h, and the radiolabelling
efficiency was determined by iTLC using an eluent of 0.1 M
sodium citrate buffer (pH 5.5). The crude reaction mixture
was purified by Sephadex-G50 size exclusion chromatogra-
phy, eluting with 100-μl fractions of phosphate-buffered
saline (pH 7.4).
In Vivo
All animal procedures were performed in accordance with
the UK Animals (Scientific Procedures) Act 1986 and with
local ethical committee approval. Xenograft tumours were
established in the right hind flank of female athymic
BALB/c nu/nu mice (Harlan) by subcutaneous injection
of Panc-1 (1 × 106) or HT1080 (1 × 106) cells in DMEM
(100 μl). When tumours reached a diameter of approxi-
mately 10 mm, [111In]anti-claudin-4 or [111In]mIgG
(5 MBq, 5 μg) in sterile PBS (100 μl) were injected
intravenously via the lateral tail vein (n = 5 for [111In]anti-
claudin-4 and n = 3 for [111In]mIgG). SPECT/CT images
were acquired using a nanoSPECT-CT scanner at 24, 48,
and 72 h after injection. After the final imaging session,
mice were euthanized by cervical dislocation, and selected
organs, tissues and blood were removed. The amount of
radioactivity in each organ was measured using a 1470
WIZARD gamma counter (PerkinElmer). Counts per
minute were converted into MBq using a calibration curve
generated from known standards. These values were decay-
corrected to the time of injection, and the percentage of the
injected dose per gram (% ID/g) of each sample was
calculated.
Genetically engineered KPC mice (K-rasLSL.G12D/+;
p53R172H/+; PdxCre; male, 3–4 months old), which were
found to be PDAC-positive by [18F]FDG-PET and MRI
screening, were also imaged by SPECT 72 h after
[111In]anti-claudin-4 or [111In]mIgG (5 MBq, 5 μg) admin-
istration (n = 3 per tracer). Further details on the imaging
protocols are included in the supplementary information.
Ex Vivo
After imaging, pancreatic cancer tissue from athymic BALB/
c nu/nu mice and KPC mice was flash-frozen with dry ice
and stored at − 80 °C overnight. Frozen tissue was sectioned
(8 μm) using an OTF5000 cryotome (Bright Instruments
Ltd). Tissue sections were thaw-mounted onto Superfrost
PLUS glass microscope slides (Menzel-Glaser, Thermo
Scientific) and allowed to dry at room temperature. The
slides were then exposed to a storage phosphor screen
(PerkinElmer, Super Resolution, 12.5 × 25.2 cm) in a
standard X-ray cassette for 15 h. The phosphor screen was
then imaged using a Cyclone® Plus Storage Phosphor
System (PerkinElmer), and images were analysed with
OptiQuant 5.0 (PerkinElmer) and ImageJ (NIH).
After autoradiography, claudin-4 levels and PDAC
morphology in ex vivo tissue were characterised by
immunofluorescence and haematoxylin and eosin (H&E)
staining, respectively. Full experimental details for H&E
staining are reported in the supplementary information.
Statistical Analyses
All statistical analyses and nonlinear regression were
performed using GraphPad Prism (GraphPad Software). An
extra sum-of-squares F test was used to compare equilibrium
dissociation constants. One- or two-way ANOVA was used
for multiple comparisons, with Tukey post-tests to calculate
significance of differences between groups. All data were
obtained in at least triplicate and results reported and
graphed as mean ± standard deviation, unless stated
otherwise.
Results
Target Validation
Western blot analysis of whole cell lysates (Fig. 1a)
confirmed the expression of claudin-4 in the Panc-1 cell
line. In contrast, claudin-4 could not be detected by Western
blot in HT1080 cells. Immunofluorescence microscopy
experiments on tissue sections obtained from Panc-1 or
HT1080 xenograft tumours showed the differential claudin-4
status in these two cell lines that was maintained when
transferred to an in vivo setting (Fig. 1b).
Binding Affinity of DTPA-Anti-Claudin-4 mAb
The binding affinity of DTPA-modified anti-claudin-4 mAb
(MAB4219) (Kd = 77.5 ± 6.8 nM; Fig. 2) was shown on
claudin-4 expressing Panc-1 cells to be comparable to that of
the unmodified antibody (Kd = 66.3 ± 7.8 nM; P 9 0.05; Fig.
2). Both DTPA-modified and unmodified anti-claudin-4
mAb exhibited negligible binding to claudin-4 negative
HT1080 cells.
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Indium-111 Labelling of DTPA-Anti-Claudin-4
mAb
[111In]anti-claudin-4 mAb was routinely synthesised in
excellent radiochemical yields (99.8 ± 0.2 %) and obtained
in high purity (9 99 %) following G50 size-exclusion
chromatography, with a typical specific activity of 1 MBq/
μg.
Imaging of Claudin-4 in Pancreatic Xenograft
Tumours
Representative SPECT/CT images obtained at 24, 48 and
72 h post-injection of [111In]anti-claudin-4 mAb or
[111In]mIgG (an isotype-matched control antibody lacking
claudin-4 specificity) are shown in Fig. 3a. Volume-of-
interest analysis revealed that uptake of [111In]anti-claudin-4
within claudin-4-overexpressing Panc-1 tumours increased
over time, yielding uptake values of 9.5 ± 1.9, 14.7 ± 3.0
and 16.9 ± 4.5 % ID/ml at 24, 48 and 72 h post-injection
(p.i.), respectively (Fig. 3b). Tumour uptake of [111In]anti-
claudin-4 in Panc-1 xenografts was significantly higher
compared to that obtained with [111In]mIgG at all time
points (P G 0.01) and with [111In]anti-claudin-4 in HT1080
tumours (P G 0.01). Furthermore, uptake of [111In]anti-
claudin-4 in HT1080 (no claudin-4 expressing) tumour
xenografts was identical to that of [111In]mIgG and therefore
did not exceed the level of non-specific uptake resulting
from the enhanced permeability and retention effect [17].
Taken together, these measurements strongly indicate that
uptake of [111In]anti-claudin-4 in Panc-1 tumour xenografts
was primarily mediated by claudin-4 expression.
The overall in vivo biodistribution of [111In]anti-claudin-4
is typical for a radiolabelled whole immunoglobulin. Due to
its long residence time within the circulation and excretion
via the hepatobiliary system, high signals can also be
observed within the blood pool (heart and carotid arteries)
and liver.
At 72 h p.i., the ex vivo biodistribution data (Table 1) was
consistent with the data extracted from the SPECT images.
Overall uptake of [111In]anti-claudin-4 was significantly higher
in Panc-1 compared with HT1080 tumours (14.3 ± 2.6 and
4.3 ± 3.0 % ID/g, respectively; P G 0.001) and was also higher
compared to uptake of [111In]mIgG in Panc-1 (6.3 ± 0.8 % ID/
g; P G 0.01) and HT1080 (5.4 ± 0.9 % ID/g; P G 0.01) tumours.
The tumour-to-blood ratio (T/B) obtained with [111In]anti-
claudin-4 at 72 h p.i. was also significantly higher for Panc-1
compared with HT1080 tumour-bearing mice (1.3 ± 0.1 and
0.4 ± 0.2, respectively; P G 0.001) and was higher compared to
the T/B values obtained with [111In]mIgG in Panc-1 (0.6 ± 0.0;
P G 0.001) and HT1080 (0.6 ± 0.2; P G 0.001) tumour-bearing
mice. Similar conclusions were drawn for tumour-to-pancreas
and tumour-to-intestines ratios, as derived from Table 1.
Autoradiography of frozen xenograft sections (Fig. 3c)
revealed higher accumulation of [111In]anti-claudin-4 within
Panc-1 tumours compared with [111In]mIgG. Furthermore,
[111In]anti-claudin-4 showed that moderate penetrative abil-
ity as radioactivity can be observed extending diffusely into
the core of the tumours.
Imaging of Claudin-4 in KPC Mice
KPC mice showing a positive indication of PDAC by
[18F]FDG-PET and MRI screening were injected with
Fig. 1. aWestern blot confirming the presence and absence
of claudin-4 on Panc-1 and HT1080 cell lysates, respectively.
b Confocal images of immunofluorescence staining of
claudin-4 (green) and nucleus (blue) in Panc-1 and HT1080
xenograft tissue. Photomicrographs show high expression of
claudin-4 in Panc-1 xenografts and negligible fluorescent
signal in claudin-4 negative tumour tissue.
Fig. 2. Determination of antibody affinity by flow cytometry.
The binding of DTPA-anti-claudin-4 mAb to claudin-4 was
found to be comparable to that of the unmodified antibody in
Panc-1 cells. Both DTPA-modified and unmodified anti-
claudin-4 mAbs exhibited negligible binding to the target
antigen in claudin-4 negative HT1080 cells.
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[111In]anti-claudin-4 or non-specific [111In]mIgG and im-
aged by SPECT. Pancreatic uptake of [111In]anti-claudin-4
in KPC mice at 72 h post-injection as measured by ex vivo
gamma-counting was found to be slightly higher when
compared to that of [111In]mIgG (3.14 ± 0.81 vs.
2.58 ± 0.80 % ID/g, see Table S1). However, pancreas-to-
blood ratios were found to be similar for both tracers
(~ 0.35), suggesting that [111In]anti-claudin-4 was unable to
provide enough contrast to delineate claudin-4 overexpres-
sion in pancreatic tissue, when the whole pancreas was
measured.
Autoradiography of KPC pancreas sections revealed that
a heterogeneous, focal distribution of [111In]anti-claudin-4
within tissue while [111In]mIgG exhibited a more diffuse
pattern of accumulation (Fig. 4 and S2, respectively). The
presence of claudin-4 and PDAC lesions in the same tissue
sections was confirmed by immunofluorescence and H&E
staining, respectively. Interestingly, co-registration of auto-
radiography, immunofluorescence and H&E images showed
a clear association between [111In]anti-claudin-4 uptake and
claudin-4 expression in pancreatic ducts affected by PDAC
(see Fig. 4).
Discussion
The progression of early preneoplastic PanIn lesions to
invasive PDAC in humans is known to occur over several
years, which provides a broad window of opportunity to
diagnose this malignancy when interventional therapy is
most likely to succeed [18]. The development of non-
invasive imaging methods capable of detecting biomarkers
associated with high-grade PanIn lesions would aid in the
Fig. 3. a Coronal and transaxial SPECT/CT images of mice bearing Panc-1 (top row) or HT1080 (bottom row) xenograft
tumours. Coronal images depict ventral views of the mice. Mice were administered either [111In]anti-claudin-4 or [111In]mIg
intravenously and SPECT/CT images were acquired at 24, 48 and 72 h post-injection. Section thickness = 0.8 mm. b Time-
activity curves generated based on volume-of-interest analysis of SPECT images showing overall tumour uptake expressed as
% ID/ml ± SEM. c Autoradiography images of Panc-1 tumour xenograft sections revealing significantly higher uptake and
penetration of [111In]anti-claudin-4 mAb compared to [111In]mIgG at 3 days p.i.
Table 1. Ex vivo biodistribution data acquired at 72 h p.i. of [111In]anti-claudin-4 mAb or [111In]mIgG
[111In]anti-claudin-4 Panc-1 (n = 5) [111In]mIgG Panc-1 (n = 3) [111In]anti-claudin-4 HT1080 (n = 5) [111In]mIgG HT1080 (n = 3)
Blood 10.61 ± 0.78 9.91 ± 1.73 10.41 ± 2.15 8.81 ± 3.24
Tumour 14.31 ± 2.60 6.26 ± 0.82 4.27 ± 3.01 5.38 ± 0.90
Heart 2.84 ± 0.47 3.71 ± 0.49 2.19 ± 0.90 2.93 ± 1.17
Lung 4.27 ± 0.44 5.13 ± 0.15 1.79 ± 1.23 4.14 ± 1.65
Liver 4.50 ± 0.59 4.13 ± 0.40 3.55 ± 0.48 4.47 ± 1.33
Spleen 5.92 ± 0.78 5.50 ± 1.50 3.19 ± 2.23 5.87 ± 1.81
Stomach 0.75 ± 0.32 0.64 ± 0.30 0.50 ± 0.14 0.37 ± 0.11
Large intestine 1.03 ± 0.19 1.20 ± 0.12 0.95 ± 0.24 0.80 ± 0.27
Small intestine 1.37 ± 0.28 1.40 ± 0.21 0.71 ± 0.27 1.23 ± 0.26
Pancreas 1.95 ± 0.40 1.96 ± 0.26 1.04 ± 0.43 1.47 ± 0.57
Kidney 4.56 ± 0.60 5.21 ± 0.28 3.34 ± 0.75 4.04 ± 0.73
Muscle 1.14 ± 0.31 1.12 ± 0.31 0.57 ± 0.23 0.83 ± 0.17
Skin 3.18 ± 0.74 3.03 ± 1.26 1.32 ± 0.85 2.04 ± 0.51
Fat 3.09 ± 1.34 2.24 ± 0.29 2.18 ± 1.08 3.50 ± 2.07
Uptake values are reported as % ID/g ± SD
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identification of patients most at risk of developing PDAC.
In recent years, several biomarkers, signalling pathways and
gene aberrations of PDAC have been discovered and are
frequently the basis of novel targeted therapies in preclinical
studies [8, 9, 19, 20]. However, examples of imaging agents
directed against these early indications of pancreatic cancer
are comparatively rare.
Considerable efforts have been made to understand the
role of claudin-4 in the development of PDAC and a variety
of other cancer types. Gene expression analyses have
revealed that claudin-4 is increasingly expressed in pancre-
atic cancer as it progresses into more advanced stages [21,
22]. Interestingly, several studies have demonstrated that
claudin-4 protein expression is associated with decreased
invasiveness and reduced metastatic potential, and it has
been positively correlated with better prognosis in PDAC [6,
23]. Similar conclusions have been drawn regarding its
involvement in colorectal cancer [24], oesophageal squa-
mous cell carcinoma [25] and gastric cancer [26–28].
Conversely, claudin-4 overexpression has been positively
correlated with increased invasiveness [29–31], metastasis
[32, 33], angiogenesis [34] and poor prognosis [35, 36] in
several other cancer types, including breast [32, 35, 37, 38],
gastric [31, 36, 39], lung [40], ovarian [29, 34, 41, 42],
prostate [33] and uterine cancers [43]. Taken together, these
results highlight the utility of claudin-4 overexpression not
only as an early detection marker for many different cancers,
but also as a cancer type-specific prognostic indicator.
Recent efforts to develop molecular imaging agents for
the detection of claudin-4 have relied on the use of CPE
fragments as targeting vectors [12, 13, 44]. While these
approaches have shown great potential for delineating
claudin-4 expression in tumour tissue and precancerous
lesions in vivo, CPE-based imaging agents suffer from poor
solubility, unknown immunogenicity and exhibit only
moderate affinity and specificity for claudin-4.
Despite their slower kinetics, antibodies are considered an
attractive alternative to CPE for molecular imaging of
claudin-4 due to their superior target affinity and specificity.
Foss and co-workers first reported specific binding of an
iodine-125 radiolabelled anti-claudin-4 mAb to claudin-4 in
subcutaneous and orthotopic xenograft models of PDAC
in vivo by SPECT imaging [45]. However, the conspicu-
ously low level of radioactivity in the blood (1.21 ± 0.77 %
ID/g) at 48 h p.i. is atypical of an antibody and is suggestive
of rapid dehalogenation which is a common issue with
radioiodinated antibodies.
In the present study, we developed a refined antibody-
based SPECT imaging agent for the delineation of claudin-4
expression in vivo. We selected a human anti-claudin-4
monoclonal antibody as a suitable targeting vector on the
basis of its high binding affinity and specificity for human
and murine claudin-4. Unlike the probe developed by Foss
et al., this antibody was specifically modified with a
bifunctional p-SCN-Bn-DTPA chelator in order to enhance
the stability of the radioimmunoconjugate. Modification of
Fig. 4. a Autoradiograph of pancreatic tissue section from KPC mouse injected with [111In]anti-claudin-4 and b corresponding
H&E photomicrograph. c, dMagnified views of representative high-uptake regions. Visual inspection of ex vivo autoradiographs
revealed a number of distinct [111In]anti-claudin-4 hotspots within tissue, while [111In]mIgG exhibited a more diffuse pattern of
distribution (Fig. S2, supplementary information). Co-registration of autoradiography, H&E and immunofluorescence images
demonstrated that [111In]anti-claudin-4 hotspots coincided with areas showing signs of PDAC pathology and claudin-4
expression, as shown by H&E staining and immunofluorescence (blue: DAPI, green: claudin-4).
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the chosen antibody with p-SCN-Bn-DTPA led to a minimal
reduction in binding affinity for the target protein. Although
indium-111 was chosen as a radiolabel in this study due to
its long half-life and ready availability, this probe could also
be adapted to PET imaging in order to facilitate quantitative
image analysis in the clinical setting.
[111In]anti-claudin-4 mAb revealed a promising ability to
bind to its target antigen in human xenograft models of
pancreatic cancer. Total uptake of [111In]anti-claudin-4 mAb
in Panc-1 tumours at 72 h p.i. was approximately 3-fold
higher compared with experimental controls. Tumour uptake
of [111In]anti-claudin-4 mAb in Panc-1 xenografts at 72 h
p.i. was markedly higher than the maximum value reported
by Foss and co-workers in the same model (4 % ID/g at 48 h
p.i.), probably due to the superior kinetic stability of the
radioimmunoconjugate [45].
Conversely, no significant differences in total pancreatic
uptake between [111In]anti-claudin-4 mAb and [111In]mIgG
were detected in the KPC mouse model. This could be due
to a more heterogeneous pattern of claudin-4 expression in
the KPC pancreas compared to human pancreatic cancer
xenografts as a result of the presence of different grade
PDAC lesions within tissue, as suggested by our immuno-
fluorescence results. Encouragingly, co-registration of auto-
radiography and histology images of pancreatic tissue
sections from KPC mice indicated that the sites showing
the most prominent [111In]anti-claudin-4 mAb accumulation
coincided with ductal regions exhibiting clear signs of
PDAC pathology and high claudin-4 expression levels.
Nevertheless, the poor contrast provided by [111In]anti-
claudin-4 mAb in the KPC model could also be the result
of limited access to the tumour mass due to the presence of
dense fibrous stroma, as well as non-specific accumulation
of the radioimmunoconjugate in the liver and spleen. Further
improvements in tumour-to-background ratios could be
feasibly achieved by utilising a smaller antibody fragment
which would undergo faster blood clearance and renal
elimination. Pretargeted imaging strategies [46] may also
offer an alternative solution, particularly as the high cell
surface persistence of claudin-4 would render it a suitable
candidate for this approach.
Conclusions
[111In]anti-Claudin-4 mAb is a useful tool for the non-
invasive SPECT imaging of claudin-4 which is a widely
dysregulated and highly prognostic biomarker in pancreatic
cancer. This imaging agent could therefore be used to aid in
the early detection and characterisation of this malignancy.
Compliance with Ethical Standards. All animal procedures were
performed in accordance with the UK Animals (Scientific Procedures) Act
1986 and with local ethical committee approval.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Funding
This research was supported by the CRUK/MRC Oxford Institute for
Radiation Oncology, Pancreatic Cancer UK and Pancreatic Cancer Research
Fund.
Open Access This article is distributed under the terms of the Creative
Commons At t r i bu t i on 4 .0 In t e rna t i ona l L i c en se (h t t p : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropri-
ate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Hidalgo M (2010) Pancreatic cancer. New Engl J Med 362:1605–
1617
2. Garcea G, Dennison AR, Pattenden CJ et al (2008) Survival following
curative resection for pancreatic ductal adenocarcinoma. A systematic
review of the literature. J Pancreas 9:99–132
3. Alazraki N (2002) Imaging of pancreatic cancer using fluorine-18
fluorodeoxyglucose positron emission tomography. J Gastrointest
Surg 6:136–138
4. Lee ES, Lee JM (2014) Imaging diagnosis of pancreatic cancer: a
state-of-the-art review. World J Gastroenterol 20:7864–7877
5. Strobel O, Buchler MW (2013) Pancreatic cancer: FDG-PET is not
useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol
Hepatol 10:203–205
6. Tsutsumi K, Sato N, Tanabe R et al (2012) Claudin-4 expression
predicts survival in pancreatic ductal adenocarcinoma. Ann Surg
Oncol 19:491–499
7. Feldmann G, Maitra A (2008) Molecular genetics of pancreatic ductal
adenocarcinomas and recent implications for translational efforts. J
Mol Diag 10:111–122
8. Harsha HC, Kandasamy K, Ranganathan P et al (2009) A compen-
dium of potential biomarkers of pancreatic cancer. PLoS Med
6:e1000046
9. Jenkinson C, Earl J, Ghaneh P et al (2015) Biomarkers for early
diagnosis of pancreatic cancer. Exp Rev Gastroenterol Hepatol 9:305–
315
10. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al (2003) Highly
expressed genes in pancreatic ductal adenocarcinomas. Cancer Res
63:8614–8622
11. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA (2004) Claudin 4
protein expression in primary and metastatic pancreatic cancer:
support for use as a therapeutic target. Am J Clin Pathol 121:226–230
12. Neesse A, Hahnenkamp A, Griesmann H et al (2013) Claudin-4-
targeted optical imaging detects pancreatic cancer and its precursor
lesions. Gut 62:1034–1043
13. Mosley M, Knight J, Neesse A et al (2015) Claudin-4 SPECT imaging
allows detection of aplastic lesions in a mouse model of breast cancer.
J Nucl Med 56:745–751
14. Kramer-Marek G, Capala J (2012) The role of nuclear medicine in
modern therapy of cancer. Tumour Biol 33:629–640
15. Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and
KrasG12D cooperate to promote chromosomal instability and widely
metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell
7:469–483
16. Brom M, Joosten L, Oyen WJ et al (2012) Improved labelling of
DTPA- and DOTA-conjugated peptides and antibodies with 111In in
HEPES and MES buffer. Eur J Nucl Med Mol Imaging Res 2:1–11
17. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique
features of tumor blood vessels for drug delivery, factors involved,
and limitations and augmentation of the effect. Adv Drug Deliv Rev
63:136–151
18. Yachida S, Jones S, Bozic I et al (2010) Distant metastasis occurs late
during the genetic evolution of pancreatic cancer. Nature 467:1114–
1117
19. Kleger A, Perkhofer L, Seufferlein T (2014) Smarter drugs emerging
in pancreatic cancer therapy. Ann Oncol 25:1260–1270
20. Tang SC, Chen YC (2014) Novel therapeutic targets for pancreatic
cancer. World J Gastroenterol 20:10825–10844
298 Torres J.B. et al.: Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma
21. Gress TM, Müller-Pillasch F, Geng M et al (1996) A pancreatic
cancer-specific expression profile. Oncogene 13:1819–1830
22. Geng MM, Ellenrieder V, Wallrapp C et al (1999) Use of
representational difference analysis to study the effect of TGFB on
the expression profile of a pancreatic cancer cell line. Gene
Chromosomes Canc 26:70–79
23. Michl P, Barth C, Buchholz M et al (2003) Claudin-4 expression
decreases invasiveness and metastatic potential of pancreatic cancer.
Cancer Res 63:6265–6271
24. Ueda J, Semba S, Chiba H et al (2007) Heterogeneous expression of
claudin-4 in human colorectal cancer: decreased claudin-4 expression
at the invasive front correlates cancer invasion and metastasis.
Pathobiology 74:32–41
25. Sung CO, Han SY, Kim SH (2011) Low expression of claudin-4 is
associated with poor prognosis in esophageal squamous cell carci-
noma. Ann Surg Oncol 18:273–281
26. Jung H, Jun KH, Jung JH, Chin HM, Park WB (2011) The expression
of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer
tissue. J Surg Res 167:e185–e191
27. Mima S, Tsutsumi S, Ushijima H et al (2005) Induction of claudin-4
by nonsteroidal anti-inflammatory drugs and its contribution to their
chemopreventive effect. Cancer Res 65:1868–1876
28. Ohtani S, Terashima M, Satoh J et al (2009) Expression of tight-
junction-associated proteins in human gastric cancer: downregulation
of claudin-4 correlates with tumor aggressiveness and survival.
Gastric Cancer 12:43–51
29. Agarwal R, D'Souza T, Morin PJ (2005) Claudin-3 and claudin-4
expression in ovarian epithelial cells enhances invasion and is
associated with increased matrix metalloproteinase-2 activity. Cancer
Res 65:7378–7385
30. Kuwada M, Chihara Y, Luo Y et al (2015) Pro-chemotherapeutic
effects of antibody against extracellular domain of claudin-4 in
bladder cancer. Cancer Lett 369:212–221
31. Hwang TL, Lee LY, Wang CC et al (2010) Claudin-4 expression is
associated with tumor invasion, MMP-2 and MMP-9 expression in
gastric cancer. Exp Therap Med 1:789–797
32. Jiwa LS, van Diest PJ, Hoefnagel LD et al (2014) Upregulation of
Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases.
BMC Cancer 14. doi:10.1186/1471-2407-14-864
33. Landers KA, Samaratunga H, Teng L et al (2008) Identification of
claudin-4 as a marker highly overexpressed in both primary and
metastatic prostate cancer. Br J Cancer 99:491–501
34. Li J, Chigurupati S, Agarwal R et al (2009) Possible angiogenic roles
for claudin-4 in ovarian cancer. Cancer Biol Ther 8:1806–1814
35. Lanigan F, McKiernan E, Brennan DJ et al (2009) Increased claudin-4
expression is associated with poor prognosis and high tumour grade in
breast cancer. Int J Cancer 124:2088–2097
36. Liu JX, Wei ZY, Chen JS et al (2015) Prognostic and clinical
significance of claudin-4 in gastric cancer: a meta-analysis. World J
Surg Oncol 13. doi:10.1186/s12957-015-0626-2
37. Ma X, Miao H, Jing B et al (2015) Claudin-4 controls the
proliferation, apoptosis, migration and in vivo growth of MCF-7
breast cancer cells. Oncol Rep 34:681–690
38. Cui YF, Liu AH, An DZ et al (2015) Claudin-4 is required for
vasculogenic mimicry formation in human breast cancer cells.
Oncotarget 6:11087–11097
39. Zhu JL, Gao P, Wang ZN et al (2013) Clinicopathological
significance of claudin-4 in gastric carcinoma. World J Surg Oncol
11. doi:10.1186/1477-7819-11-150
40. Yamada G, Murata M, Takasawa A et al (2016) Increased expressions
of claudin 4 and 7 in atypical adenomatous hyperplasia and
adenocarcinoma of the lung. Med Mol Morphol 49:163–169
41. Choi YL, Kim J, Kwon MJ et al (2007) Expression profile of tight
junction protein claudin 3 and claudin 4 in ovarian serous adenocar-
cinoma with prognostic correlation. Histol Histopathol 22:1185–1195
42. Rangel LBA, Agarwal R, D'Souza T et al (2003) Tight junction
proteins claudin-3 and claudin-4 are frequently overexpressed in
ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res
9:2567–2575
43. Pan XY, Li X, Che YC, Li HY, Zhang Y, Yang X (2013)
Overexpression of claudin-4 may be involved in endometrial
tumorigenesis. Oncol Lett 5:1422–1426
44. Cocco E, Shapiro EM, Gasparrini S et al (2015) Clostridium
Perfringens enterotoxin C-terminal domain labeled to fluorescent dyes
for in vivo visualization of micrometastatic chemotherapy-resistant
ovarian cancer. Int J Cancer 137:2618–2629
45. Foss CA, Fox JJ, Feldmann G et al (2007) Radiolabeled anti-claudin 4
and anti-prostate stem cell antigen: initial imaging in experimental
models of pancreatic cancer. Mol Imaging 6:131–139
46. Knight JC, Cornelissen B (2014) Bioorthogonal chemistry: implica-
tions for pretargeted nuclear (PET/SPECT) imaging and therapy. Am
J Nucl Med Mol Imaging 4:96–113
Torres J.B. et al.: Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma 299
